Mirror Biologics Inc. Initiates AlloStim® Phase IIB Clinical Trial for Metastatic Colorectal Cancer
Mirror Biologics, Inc., a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which
RenalSense Partners with Medline on Clarity RMS
Jerusalem based RenalSense Ltd., a privately-held medical device company and developer of Clarity RMS™, and Medline Industries, Inc., a leading global healthcare manufacturer and distributor,
VizibleZone Provides COVID-19 Exposure Notification Solution to the Israeli National Water Company
Jerusalem-based Artificial Intelligence (AI) startup VizibleZone today announced a deal with Mekorot, Israel’s National Water Company, to use VizibleZone‘s high accuracy exposure notification technology in
VOTIS Subdermal Imaging Raises US$2.5 Million
Jerusalem based VOTIS Subdermal Imaging Technologies, Ltd. has raised US$2.5 million in a private placement of equity to a consortium of investors in Israel, Italy,
Memorial Hermann Health System Former President & CEO, Dan Wolterman, appointed BactoByte Chair
BactoByte has appointed Mr. Dan Wolterman, Former President and CEO of Memorial Hermann Health System, as a Board Chair. With more than 40 years of
Respinova Granted FDA 510(k) Clearance for Pulsehaler
Respinova has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Pulsehaler™. Pulsehaler™ is an innovative device that facilitates the opening
KAHR’s Anti-CD47 in Blood Cancers Clinical Trials Funded by Texas MD Anderson Cancer Focus Fund
KAHR, a Jerusalem based clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, and Cancer Focus Fund, LP, a unique venture capital fund established in
Jerusalem Startup eggXYt Launches Bid to Disrupt The Egg Industry
eggXYt, a Jerusalem-based genetic tech startup, is developing technology to save billions of baby chickens from unnecessary death, while generating significant savings for farmers. eggXYt
SpliSense Raises $28.5 Million for Treatment of CF
Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, announced on Thursday the closing of
